Analysis of clinical factors associated with incomplete standard protocol 177Lu-DOTATATE treatment in neuroendocrine tumor patients
In this study, the presence of SRS-positive bone metastases and low hemoglobin levels were significant factors associated with the inability to complete <sup>177</sup>Lu-DOTATATE treatment for NET patients. Extensive bone metastases, such as diffuse metastasis or more than 20 bone metastases, may be particularly associated with the inability to administer standard protocol treatment.
Authors
- Shigeyasu Sugawara (ORCID: https://orcid.org/0000-0002-8795-8099)
- Hayato Go (ORCID: https://orcid.org/0000-0002-0138-6676)
- Shiro Ishii (ORCID: https://orcid.org/0000-0002-5274-877X)
- Noboru Oriuchi (ORCID: https://orcid.org/0000-0002-5557-0620)
- Hiroshi Ito (ORCID: https://orcid.org/0000-0002-3581-4798)
- Shozo Okamoto
- Tohru Shiga (ORCID: https://orcid.org/0000-0002-3238-3507)
Institutions
- Fukushima Medical University (JP)
Publication Details
- Journal
- Japanese Journal of Radiology
- Published
- 2025-03-29
- DOI
- https://doi.org/10.1007/s11604-025-01769-7
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35